Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas.
Ellis R, Tang D, Nasr B, Greenwood A, McConnell A, Anagnostou ME, Elias M, Verykiou S, Bajwa D, Ewen T, Reynolds NJ, Barrett P, Carling E, Watson G, Armstrong J, Allen AJ, Horswell S, Labus M, Lovat PE. Ellis R, et al. Br J Dermatol. 2020 Jan;182(1):156-165. doi: 10.1111/bjd.18086. Epub 2019 Jun 19. Br J Dermatol. 2020. PMID: 31056744 Free PMC article.
Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model.
Vale L, Kunonga P, Coughlan D, Kontogiannis V, Astin M, Beyer F, Richmond C, Wilson D, Bajwa D, Javanbakht M, Bryant A, Akor W, Craig D, Lovat P, Labus M, Nasr B, Cunliffe T, Hinde H, Shawgi M, Saleh D, Royle P, Steward P, Lucas R, Ellis R. Vale L, et al. Health Technol Assess. 2021 Nov;25(64):1-178. doi: 10.3310/hta25640. Health Technol Assess. 2021. PMID: 34792018 Free article.
An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial).
Sach TH, Thomas KS, Batchelor JM, Perways A, Chalmers JR, Haines RH, Meakin GD, Duley L, Ravenscroft JC, Rogers A, Santer M, Tan W, White J, Whitton ME, Williams HC, Cheung ST, Hamad H, Wright A, Ingram JR, Levell N, Goulding JMR, Makrygeorgou A, Bewley A, Ogboli M, Stainforth J, Ferguson A, Laguda B, Wahie S, Ellis R, Azad J, Rajasekaran A, Eleftheriadou V, Montgomery AA; UK Dermatology Clinical Trials Network’s HI-Light Vitiligo Trial Team. Sach TH, et al. Br J Dermatol. 2021 May;184(5):840-848. doi: 10.1111/bjd.19554. Epub 2020 Nov 4. Br J Dermatol. 2021. PMID: 32920824 Clinical Trial.
Melanoma secretion of transforming growth factor-β2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration.
Cosgarea I, McConnell AT, Ewen T, Tang D, Hill DS, Anagnostou M, Elias M, Ellis RA, Murray A, Spender LC, Giglio P, Gagliardi M, Greenwood A, Piacentini M, Inman GJ, Fimia GM, Corazzari M, Armstrong JL, Lovat PE. Cosgarea I, et al. Among authors: ellis ra. Br J Dermatol. 2022 Apr;186(4):694-704. doi: 10.1111/bjd.20889. Epub 2021 Dec 27. Br J Dermatol. 2022. PMID: 34773645 Free PMC article.
Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial.
Thomas KS, Batchelor JM, Akram P, Chalmers JR, Haines RH, Meakin GD, Duley L, Ravenscroft JC, Rogers A, Sach TH, Santer M, Tan W, White J, Whitton ME, Williams HC, Cheung ST, Hamad H, Wright A, Ingram JR, Levell NJ, Goulding JMR, Makrygeorgou A, Bewley A, Ogboli M, Stainforth J, Ferguson A, Laguda B, Wahie S, Ellis R, Azad J, Rajasekaran A, Eleftheriadou V, Montgomery AA; UK Dermatology Clinical Trials Network’s HI-Light Vitiligo Trial Team. Thomas KS, et al. Br J Dermatol. 2021 May;184(5):828-839. doi: 10.1111/bjd.19592. Epub 2020 Dec 28. Br J Dermatol. 2021. PMID: 33006767 Clinical Trial.
136 results